Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China.
Tongxiang Hospital of Traditional Chinese Medicine, Zhejiang, China.
Mini Rev Med Chem. 2024;24(9):895-907. doi: 10.2174/1389557523666230915103121.
Lymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NHL, especially in diffuse large B cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), and follicular lymphoma (FL). The technologies discussed include clinical imaging, targeted drug delivery, photodynamic therapy (PDT), and thermodynamic therapy (TDT) for lymphoma. This review aims to provide a better understanding of the use of nanotechnology in the treatment of non-Hodgkin's lymphoma.
淋巴瘤是全球第八大常见癌症类型。目前，淋巴瘤主要分为两大主要类型：霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL），其中 NHL 占病例的 80%至 90%。NHL 主要分为 B 细胞、T 细胞和自然杀伤（NK）细胞淋巴瘤。纳米技术发展迅速，为医学领域做出了重大贡献。本综述总结了近年来纳米生物技术的进展及其在 NHL 治疗中的应用，特别是在弥漫性大 B 细胞淋巴瘤（DLBCL）、原发性中枢神经系统淋巴瘤（PCNSL）和滤泡性淋巴瘤（FL）中的应用。讨论的技术包括用于淋巴瘤的临床成像、靶向药物输送、光动力疗法（PDT）和热疗（TDT）。本综述旨在更好地了解纳米技术在治疗非霍奇金淋巴瘤中的应用。
Mini Rev Med Chem. 2024
Eur J Haematol Suppl. 2007-1
Expert Opin Biol Ther. 2013-5
Mater Today Bio. 2025-7-3
Cancers (Basel). 2023-4-12
Int J Mol Sci. 2022-8-10
Chem Asian J. 2022-8-15
Abdom Radiol (NY). 2022-8
Front Bioeng Biotechnol. 2022-3-28
Cancers (Basel). 2022-3-11
Zotero 插件